Commentary for the Missing Data Working Group's perspective for regulatory clinical trials, estimands, and sensitivity analyses

被引：2

作者：

Koch, Gary G. ^{[1
]}

Wiener, Laura Elizabeth ^{[1
]}

机构：

[1] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA

来源：

STATISTICS IN MEDICINE | 2016年 / 35卷 / 17期

关键词：

TO-EVENT DATA; INTERVENTION EFFECTIVENESS CATIE; ANTIPSYCHOTIC TRIALS; DOUBLE-BLIND; TIME; PLACEBO; OSTEOARTHRITIS; ACETAMINOPHEN; MULTICENTER; COVARIANCE;

D O I：

10.1002/sim.6954

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页码：2887 / 2893

页数：7

共 50 条

[41] Methods for imputing missing data for Parkinson's disease clinical trials with multiple correlated outcomes
Luo, S.
He, B.
Elm, J.
Tilley, B.
[J]. MOVEMENT DISORDERS, 2013, 28 : S170 - S170
[42] The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG)
Tremaine, Larry
Brian, William
DelMonte, Terrye
Francke, Stephan
Groenen, Peter
Johnson, Keith
Li, Lei
Pearson, Kimberly
Marshall, Jean-Claude
[J]. PHARMACOGENOMICS, 2015, 16 (18) : 2055 - 2067
[43] Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problems and solutions
Hahn, EA
Webster, KA
Cella, D
Fairclough, DL
[J]. STATISTICS IN MEDICINE, 1998, 17 (5-7) : 547 - 559
[44] Group comparisons involving missing data in clinical trials: a comparison of estimates and power (size) for some simple approaches
Miller, ME
Morgan, TM
Espeland, MA
Emerson, SS
[J]. STATISTICS IN MEDICINE, 2001, 20 (16) : 2383 - 2397
[45] Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson's Disease: A Regulatory Perspective
Sacks, Leonard
Kunkoski, Elizabeth
[J]. JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S111 - S115
[46] How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients?
Coley, N.
Gardette, V.
Cantet, C.
Gillette-Guyonnet, S.
Nourhashemi, F.
Vellas, B.
Andrieu, S.
[J]. CURRENT ALZHEIMER RESEARCH, 2011, 8 (04) : 421 - 433
[47] ASSESSING THE RISK OF BIAS IN CLINICAL TRIALS FOR HEALTH TECHNOLOGY ASSESSMENTS: SHOULD EXISTING TOOLS REFLECT THE ICH E9(R1) ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSES?
Poythress, J.
Morga, A.
[J]. VALUE IN HEALTH, 2023, 26 (12) : S329 - S329
[48] Critical Path for Parkinson's: Catalyzing Innovation for Parkinson's Clinical Trials through Data Sharing and Regulatory Science
Stephenson, Diane
Akalu, Mussie
Alexander, Robert
Bloem, Bastiaan
Boroojerdi, Babak
Bravi, Daniele
Burn, David
Cedarbaum, Jesse
Conrado, Daniela
Dorsey, E. Ray
Facheris, Maurizio
Fischer, Tanya
Frasier, Mark
Gallagher, Jill
Gordon, Mark
Graff, Ole
Grosset, Donald
Sheikh, Zulfiqar Haider
Hill, Derek
Ho, Carole
Hu, Michele
Hynds, Renee
Kieburtz, Karl
Lawson, Rachael
Macha, Sreeraj
Manolis, Efthymios
Marek, Kenneth
Matthews, Dawn
Nicholas, Timothy
Podskalny, Gerald
Post, Anke
Romero, Klaus
Russell, David
Seibyl, John
Stafford, Bob
Stebbins, Glenn
Tome, Maria
Venuto, Charles
Williams-Gray, Caroline
Yarnall, Alison
Dexter, David
[J]. NEUROLOGY, 2019, 92 (15)
[49] Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)
J. Shuren
P. M. Doraiswamy
[J]. The Journal of Prevention of Alzheimer's Disease, 2022, 9 : 236 - 240
[50] Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective
Ghadessi, Mercedeh
Di, Junrui
Wang, Chenkun
Toyoizumi, Kiichiro
Shao, Nan
Mei, Chaoqun
Demanuele, Charmaine
Tang, Rui
McMillan, Gianna
Beckman, Robert A.
[J]. ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)

← 1 2 3 4 5 →